Generon has established a pipeline with assets at various stages of clinical development. Each product candidate meets the following four criteria: has intellectual property rights, has a competitive advantage in global markets, is an antibody (Ab) or antibody-like chemical entity (or large molecule biologic), addresses an unmet medical need.

All products are generated either from Generoní»s DiKineTM or ITabTM platforms. F-627 is potentially a best-in-class therapy to compete with existing recombinant human granulocyte colony-stimulating factors (rhG-CSF). F-652 is a first-in-class recombinant human interleukin 22 (IL-22) treating acute inflammatory/immunological diseases including graft vs host disease (GvHD), acute alcoholic hepatitis (AH), and acute pancreatitis (AP). Generoní»s immune-oncology (I/O) pipeline consists of multiple CD3 bi-specific antibodies generated from the ITabTM platform. These CD3 bi-specific antibodies are at pre-clinical development and early clinical development stages.